Pacira BioSciences (NASDAQ:PCRX) Earns “Neutral” Rating from HC Wainwright

Pacira BioSciences (NASDAQ:PCRX)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $36.50 price objective on the stock, down from their prior price objective of $38.00. HC Wainwright’s target price suggests a potential upside of 0.30% from the company’s current price.

Several other equities research analysts have also issued reports on PCRX. Oppenheimer initiated coverage on Pacira BioSciences in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $32.00 price objective for the company. Jefferies Financial Group restated a “hold” rating and issued a $36.00 target price on shares of Pacira BioSciences in a research note on Thursday. Weiss Ratings cut Pacira BioSciences from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, September 16th. Truist Financial lifted their price target on Pacira BioSciences from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. raised Pacira BioSciences from an “underweight” rating to a “neutral” rating and set a $36.50 price objective for the company in a report on Thursday. Two equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Pacira BioSciences has a consensus rating of “Hold” and a consensus price target of $31.44.

Pacira BioSciences Stock Performance

NASDAQ PCRX opened at $36.39 on Friday. Pacira BioSciences has a 1 year low of $18.80 and a 1 year high of $36.46. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.04 and a quick ratio of 3.94. The stock has a market capitalization of $1.45 billion, a PE ratio of 103.97 and a beta of 0.25. The company’s 50 day simple moving average is $25.37 and its two-hundred day simple moving average is $24.51.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.65 by $0.08. The firm had revenue of $192.40 million during the quarter, compared to the consensus estimate of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $0.74 EPS. Analysts predict that Pacira BioSciences will post 1.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $23.23, for a total transaction of $70,619.20. Following the sale, the insider owned 216,384 shares in the company, valued at $5,026,600.32. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pacira BioSciences

A number of large investors have recently modified their holdings of the company. PNC Financial Services Group Inc. increased its position in shares of Pacira BioSciences by 15.1% during the first quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock valued at $85,000 after buying an additional 492 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Pacira BioSciences by 10.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 11,746 shares of the company’s stock worth $268,000 after buying an additional 1,142 shares during the period. State of Wyoming lifted its holdings in Pacira BioSciences by 10.2% in the first quarter. State of Wyoming now owns 12,298 shares of the company’s stock worth $278,000 after buying an additional 1,143 shares during the period. Hsbc Holdings PLC grew its holdings in shares of Pacira BioSciences by 7.7% during the 4th quarter. Hsbc Holdings PLC now owns 18,416 shares of the company’s stock worth $479,000 after acquiring an additional 1,316 shares during the period. Finally, Global Retirement Partners LLC bought a new position in shares of Pacira BioSciences in the 2nd quarter worth approximately $51,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris acquisition: Viatris will acquire Pacira’s marketed non-opioid pain products, including EXPAREL and ZILRETTA. The deal is expected to close by the end of 2026, subject to customary conditions, and Viatris expects it to be immediately accretive to its financial guidance metrics. Viatris Agrees to Acquire Pacira BioSciences
• Positive Sentiment: Analyst support: Pacira received an analyst upgrade, helping reinforce momentum following the takeover announcement. JPMorgan also raised its rating from “underweight” to “neutral” and set a $36.50 price target, broadly aligning with the proposed cash consideration. Pacira Stock Jumps on Analyst Upgrade
• Neutral Sentiment: Truist increased its price target to $31 while maintaining a “buy” rating, but the target is below the $36.50 acquisition price and is therefore less relevant if the deal closes. Jefferies and Needham reiterated “hold” ratings. Pacira Price Target Increase
• Negative Sentiment: Several shareholder law firms announced investigations into whether Pacira’s board obtained sufficient value for shareholders and conducted an adequate sale process. These reviews could create litigation or deal-execution risk, although no specific wrongdoing has been established. Shareholder Investigation

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.